Brii Biosciences Limited (2137.HK)
HKD 0.85
(0.0%)
HKD 0.85
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -168.2 Million CNY | 14.45% |
| 2022 | -503.58 Million CNY | 88.06% |
| 2021 | -602.79 Million CNY | -236.69% |
| 2020 | -890.78 Million CNY | -141.95% |
| 2019 | -124.11 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -106.64 Million CNY | 0.0% |
| 2024 Q1 | -106.64 Million CNY | 22.5% |
| 2023 Q4 | -137.6 Million CNY | 0.0% |
| 2023 FY | - CNY | 14.45% |
| 2023 Q3 | -137.6 Million CNY | -5.0% |
| 2023 Q2 | -131.05 Million CNY | 0.0% |
| 2023 Q1 | -131.05 Million CNY | -55.99% |
| 2022 Q2 | -168.73 Million CNY | 0.0% |
| 2022 Q1 | -168.73 Million CNY | 20.9% |
| 2022 FY | - CNY | 88.06% |
| 2022 Q4 | -84.01 Million CNY | 0.0% |
| 2022 Q3 | -84.01 Million CNY | 50.21% |
| 2021 Q1 | -88.08 Million CNY | 71.0% |
| 2021 FY | - CNY | -236.69% |
| 2021 Q3 | -213.31 Million CNY | -142.17% |
| 2021 Q4 | -213.31 Million CNY | 0.0% |
| 2021 Q2 | -88.08 Million CNY | 0.0% |
| 2020 FY | - CNY | -141.95% |
| 2020 Q4 | -303.69 Million CNY | 0.0% |
| 2020 Q3 | -303.69 Million CNY | -114.33% |
| 2020 Q2 | -141.69 Million CNY | 0.0% |
| 2020 Q1 | -141.69 Million CNY | 0.0% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 284.363% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 134.553% |